These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 15673502)

  • 21. Clostridium difficile in children: colonisation and disease.
    Enoch DA; Butler MJ; Pai S; Aliyu SH; Karas JA
    J Infect; 2011 Aug; 63(2):105-13. PubMed ID: 21664931
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rifaximin in the treatment of recurrent Clostridium difficile infection.
    Mattila E; Arkkila P; Mattila PS; Tarkka E; Tissari P; Anttila VJ
    Aliment Pharmacol Ther; 2013 Jan; 37(1):122-8. PubMed ID: 23095030
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduction in Clostridium difficile environmental contamination by hospitalized patients treated with fidaxomicin.
    Biswas JS; Patel A; Otter JA; Wade P; Newsholme W; van Kleef E; Goldenberg SD
    J Hosp Infect; 2015 Jul; 90(3):267-70. PubMed ID: 25728208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clostridium difficile infection in the "oldest" old: clinical outcomes in patients aged 80 and older.
    Cober ED; Malani PN
    J Am Geriatr Soc; 2009 Apr; 57(4):659-62. PubMed ID: 19392957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clostridium difficile infection: epidemiology, disease burden and therapy].
    Gulácsi L; Kertész A; Kopcsóné Németh I; Banai J; Ludwig E; Prinz G; Reményi P; Strbák B; Zsoldiné Urbán E; Baji P; Péntek M; Brodszky V
    Orv Hetil; 2013 Jul; 154(30):1188-93. PubMed ID: 23876616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Re-emergent etiologies: Clostridium difficile].
    Mare A; Man A; Toma F; Szekely E; Lörinczi L
    Bacteriol Virusol Parazitol Epidemiol; 2007; 52(3-4):181-8. PubMed ID: 19326731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of first recurrence in Clostridium difficile-associated disease. A study of 306 patients hospitalized in a Romanian tertiary referral center.
    Lupse M; Flonta M; Cioara A; Filipescu I; Todor N
    J Gastrointestin Liver Dis; 2013 Dec; 22(4):397-403. PubMed ID: 24369321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of treatment patterns and patient outcomes before vs after implementation of a severity-based Clostridium difficile infection treatment policy.
    Jardin CG; Palmer HR; Shah DN; Le F; Beyda ND; Jiang Z; Garey KW
    J Hosp Infect; 2013 Sep; 85(1):28-32. PubMed ID: 23834988
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comment on: Increasing incidence of community-associated atypical Clostridium difficile disease in children.
    Pant C; Bass PF
    Clin Pediatr (Phila); 2010 Sep; 49(9):907; author reply 908. PubMed ID: 20693524
    [No Abstract]   [Full Text] [Related]  

  • 30. Clostridium difficile-associated diarrhea: resurgence with a vengeance.
    Oldfield EC
    Rev Gastroenterol Disord; 2006; 6(2):79-96. PubMed ID: 16699477
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of outcomes with vancomycin or metronidazole for mild-to-moderate Clostridium difficile associated diarrhea among solid organ transplant recipients: A retrospective cohort study.
    Nguyen CT; Li J; Anders S; Garcia-Diaz J; Staffeld-Coit C; Hand J
    Transpl Infect Dis; 2018 Jun; 20(3):e12867. PubMed ID: 29512244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A study of Clostridium difficile-associated disease at King Chulalongkorn Memorial Hospital, Thailand.
    Pupaibool J; Khantipong M; Suankratay C
    J Med Assoc Thai; 2008 Jan; 91(1):37-43. PubMed ID: 18386542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk factors for recurrent Clostridium difficile infection in a tertiary hospital in Israel.
    Na'amnih W; Adler A; Miller-Roll T; Cohen D; Carmeli Y
    Eur J Clin Microbiol Infect Dis; 2018 Jul; 37(7):1281-1288. PubMed ID: 29627951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treating C. difficile.
    Parmar MS
    CMAJ; 2005 Feb; 172(4):448; author reply 448. PubMed ID: 15710921
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical manifestations, treatment and control of infections caused by Clostridium difficile.
    Bouza E; Muñoz P; Alonso R
    Clin Microbiol Infect; 2005 Jul; 11 Suppl 4():57-64. PubMed ID: 15997485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New and emerging therapies in treatment of Clostridium difficile infection.
    Goyal H; Perisetti A; Rehman MR; Singla U
    Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):589-597. PubMed ID: 29521664
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recurrent refractory Clostridium difficile colitis treated successfully with rifaximin and tigecycline: a case report and review of the literature.
    El-Herte RI; Baban TA; Kanj SS
    Scand J Infect Dis; 2012 Mar; 44(3):228-30. PubMed ID: 22077098
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clostridium difficile and Entamoeba histolytica infections in patients with colitis in the Philippines.
    Warren CA; Labio E; Destura R; Sevilleja JE; Jamias JD; Daez ML
    Trans R Soc Trop Med Hyg; 2012 Jul; 106(7):424-8. PubMed ID: 22657531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clostridium difficile-associated disease: new challenges from an established pathogen.
    Sunenshine RH; McDonald LC
    Cleve Clin J Med; 2006 Feb; 73(2):187-97. PubMed ID: 16478043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity.
    Zar FA; Bakkanagari SR; Moorthi KM; Davis MB
    Clin Infect Dis; 2007 Aug; 45(3):302-7. PubMed ID: 17599306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.